PMID: 8601224Apr 1, 1996Paper

A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association
M A FischlR T Steigbigel

Abstract

To assess safety, antitumor response, and immunological and virological activity of interferon-alpha 2a and zidovudine combination therapy in patients with AIDS-related Kaposi's sarcoma, we conducted an open-label, Phase II, multicenter study. Sixty-three patients with biopsy-proven Kaposi's sarcoma and no previous interferon-alpha therapy received zidovudine 600 mg/day and interferon-alpha 2a 18 x 10(6) U/day. The median duration of follow-up was 49 weeks. Of 62 evaluable patients, 25 (40%; 95% confidence interval, 0.28-0.52) showed a complete (26%) or partial (15%) antitumor response. Eight of 30 patients (27%) with < 100 CD4 cells/mm3 and 17 of 32 patients (53%) with > or = 100 CD4 cells/mm3 had a response. The median time to response was 36 weeks. Of the 25 patients with a response, four developed tumor progression. The median duration of response was 22.4 weeks. Eight patients (13%) developed another AIDS-defining event and 13 (21%) died. The major toxicities included anemia (16%), neutropenia (27%), elevated serum transaminases (16%), weight loss (16%), malaise (14%), fatigue (14%), fever (10%), and headache (6%). Therapy with intermediate-dose interferon-alpha 2a and zidovudine resulted in tumor regression in patients wi...Continue Reading

References

Apr 16, 1992·The New England Journal of Medicine·N M GrahamJ P Phair
Feb 1, 1987·Cancer·P A VolberdingR J Spiegel
Apr 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A RiosJ U Gutterman
Apr 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F X RealS E Krown
Jan 1, 1984·Annals of the New York Academy of Sciences·S E KrownH F Oettgen
Jan 1, 1984·Annals of the New York Academy of Sciences·P VolberdingG Gee

❮ Previous
Next ❯

Citations

Jul 11, 2003·Hematology/oncology Clinics of North America·Jamie H Von Roenn
Sep 14, 2001·Current Opinion in Oncology·S E Krown
Aug 13, 2002·European Journal of Gastroenterology & Hepatology·Roel E SentjensHenk W Reesink
Aug 12, 2005·Current Opinion in Oncology·Carmen Manuela Klass, Margaret K Offermann
Nov 1, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sundar SanthanamKen O'Byrne
May 30, 2002·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Susan E KrownMarcia A Testa
Feb 23, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Erin ReidDeborah A Freedman-Cass
Sep 28, 2004·The Journal of General Virology·Veronika P PozharskayaMargaret K Offermann
Jul 10, 2001·Journal of Clinical Periodontology·K F Al-ShammariH L Wang
May 15, 2002·Clinical Oral Implants Research·Robert HaasGeorg Watzek
May 10, 2000·The Oncologist·L Rosen
Aug 26, 1998·Journal of the National Cancer Institute. Monographs·S E Krown
Oct 2, 2020·Viruses·Nedaa Alomari, Jennifer Totonchy
May 20, 1998·Dermatologic Clinics·R Stadler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.